Infosys Buyback 2025 vs Nectar Lifesciences Buyback 2025

Comparison between Infosys Buyback 2025 and Nectar Lifesciences Buyback 2025.

Buyback Details

Infosys Buyback 2025 is a Tender Offer buyback proposed to list at BSE, NSE while Nectar Lifesciences Buyback 2025 is a Tender Offer proposed to list at BSE, NSE.

 Infosys Ltd.Nectar Lifesciences Ltd.
LogoInfosys Buyback 2025 LogoNectar Lifesciences Buyback 2025 Logo
Type of BuybackTender OfferTender Offer
Listing AtBSE, NSEBSE, NSE
Face Value₹5 per share₹1 per share
Buyback Price₹1800 per share₹27 per share
Issue Size10,00,00,000 shares3,00,00,000 shares
Issue Size (Amount)₹18,000.00 Crores₹81.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders2 Equity Shares out of every 11 Fully paid-up Equity Shares held on the Record Date.1,50,00,000
General Category for all other Eligible Shareholders17 Equity Shares out of every 706 Fully paid-up Equity Shares held on the Record Date.8,50,00,000
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,32,51,651
General Category for all other Eligible Shareholders25 Equity Shares out of every 103 Fully paid-up Equity Shares held on the Record Date.1,67,48,349
RegistrarKfin Technologies Ltd.Kfin Technologies Ltd.
Lead ManagersKotak Mahindra Capital Co.Ltd.Master Capital Services Ltd.
Necessity of the buyback

The Company is undertaking the Buyback after considering its strategic and operational cash needs in the medium term, as well as the need to return surplus funds to members effectively and efficiently, in line with its capital allocation policy. The financial parameters internal factors considered include, but are not limited to:

  • Expected cash requirements of the Company towards working capital, investments in AI and other areas, capital expenditure in technology and infrastructure, etc.
    Investments required towards execution of the Company's strategy:
    Funds are necessary for any acquisitions that the Board may approve. Minimum cash required for contingencies or unforeseen events; Any other significant developments that require cash investments
  • As of June 30, 2025, the Company had consolidated cash and investments (comprising cash and cash equivalents, current and non-current investments excluding investments in equity and preference shares and others) of 45,204 crore
  • The Buyback is being undertaken for the following reasons:The Buyback will help the Company to return surplus cash to its members, in line with the stated Capital Allocation Policy. The Buyback is expected to improve return on equity through distribution of money and improve earnings per share by reduction in the equity base in the long term, thereby leading to long-term increase in members' value.
    The Buyback gives an option to all the members of the Company as on the Record Date, either to sell their Equity Shares and receive cash or not to sell their Equity Shares and get a resultant increase in their percentage shareholding in the Company post the Buyback, without additional investment, and
    The Buyback, which is being implemented through the Tender Offer route, would involve allocating to the Small Shareholders the higher of (a) the number of shares entitled as per their shareholding or (b) 15% of the number of shares to be repurchased, as per Regulation 6 of the Buyback Regulations. The Company believes that this reservation for small shareholders would benefit a large number of the Company's public shareholders, who would be classified as "Small Shareholders.
  • The buyback will help the company to return surplus cash to its shareholders holding equity shares broadly in proportion to their shareholding, thereby, enhancing the overall return to shareholders.
  • The buyback will help the company to optimize the capital structure;
  • The Buyback, which is being implemented through the Tender Offer route as prescribed under the SEBI Buyback Regulations, would involve allocation of the number of equity shares as per their entitlement or 15% of the number of equity shares to be bought back, whichever is higher, reserved. The company believes that the reservation for small shareholders would benefit a large number of the Company's public shareholders, who get classified as "Small Shareholders, as per regulations 2(i)(n) of the SEBI Buyback Regulations.
  • The buyback may help in improving financial ratios like earnings per share, return on capital employed, and return on equity, by reduction in the equity base, thereby leading to long-term increase in shareholders' vlaue; and
  • The buyback gives an option to the shareholders holding Equity shares of the company, who can choose to participate and get cash in lieu of Equity shares to be accepted under the Buyback offer or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the buyback offer, without additional investment.

Buyback Timetable

Infosys Buyback 2025 and Nectar Lifesciences Buyback 2025 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Infosys Buyback 2025 Buyback record date is Nov 14, 2025. Nectar Lifesciences Buyback 2025 Buyback record date is Dec 24, 2025.

 Infosys Ltd.Nectar Lifesciences Ltd.
Record DateNov 14, 2025Dec 24, 2025
Offer Open DateNov 20, 2025Dec 31, 2025
Offer Closure DateNov 26, 2025Jan 06, 2026
Last date for receipt of tender formsNov 26, 2025Jan 06, 2026
Finalisation of buybackDec 02, 2025Jan 12, 2026
Last Date for settlment of bidsDec 03, 2025Jan 13, 2026
Last Date for extinguishment of sharesDec 12, 2025Jan 22, 2026

Financial Details and Other Relevent Information

Comparison of Infosys Buyback 2025 and Nectar Lifesciences Buyback 2025 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

 Infosys Ltd.Nectar Lifesciences Ltd.
Financial

Infosys Limited Financial Information (Restated Consolidated)

Infosys Limited's revenue increased by 5% and profit after tax (PAT) rose by 2% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended31 Mar 202531 Mar 2024
Assets1,48,903.001,37,814.00
Total Income1,66,590.001,58,381.00
Profit After Tax26,750.0026,248.00
Reserves and Surplus12,116.0015,092.00
Amount in ₹ Crore

Company Financials (Restated Consolidated)

Nectar Lifesciences Ltd.'s revenue decreased by 1% and profit after tax (PAT) dropped by 2376% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Income11.301,674.971,698.661,566.85
Profit After Tax-1.01-113.684.99-24.18
NET Worth716.87956.111,069.251,064.59
Reserves and Surplus694.44933.681,046.821,042.17
Total Borrowing458.85582.02635.54753.83
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Sep-2025 1554.80 1428.35 1491.78
Aug-2025 1539.00 1414.50 1464.26
Jul-2025 1649.00 1482.70 1581.61

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.75 14.67
Oct-2025 16.01 13.31 14.26
Sep-2025 17.03 14.07 15.15
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Sep-2025 1555.00 1428.30 1491.90
Aug-2025 1539.00 1414.00 1464.26
Jul-2025 1649.00 1482.50 1581.56

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Nov-2025 16.99 13.71 14.64
Oct-2025 15.76 13.10 14.18
Sep-2025 16.99 14.03 15.12

Compare with others

Compare:

Infosys Buyback 2025 and Nectar Lifesciences Buyback 2025